Scholarlink

<p>The continued emergence of drug resistant <i>Mycobacterium tuberculosis</i> highlights the pressing need for novel therapeutic strategies targeting essential and underexploited bacterial pathways. In this study, an integrated in silico approaches was employed to rationally design benzofuro [3,2-d] pyrimidine-based inhibitors targeting mycobacterial membrane protein Large 3 (MmpL3), a key transporter involved in mycolic acid biosynthesis. A structure-based e-pharmacophore model comprising six energetically significant features was developed from the MmpL3 crystal structure (PDB ID: 7C2M) and used to screen a curated ChEMBL dataset, reducing 5752 compounds to 278 candidates. Subsequent QSAR modeling demonstrated robust predictive performance (R2 = 0.65, Q2 = 0.63), enabling activity-guided prioritization. Hierarchical molecular docking and MM-GBSA calculations identified three lead compounds (D3, D12, and D16) with enhanced binding affinities (ΔG<sub>bind</sub> =  − 50.96– − 56.36&#xa0;kcal/mol) relative to the reference ligand (− 49.85&#xa0;kcal/mol). Molecular dynamics simulations over 200&#xa0;ns confirmed the structural stability of the MmpL3–ligand complexes, with backbone RMSD values stabilizing below 2.6&#xa0;Å and persistent hydrogen bonding within the binding cavity. ADMET profiling indicated favorable oral bioavailability and acceptable drug-likeness. Collectively, these findings highlight benzofuro[3,2-d]pyrimidine scaffolds as promising leads for MmpL3-targeted anti-tuberculosis drug development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design of benzofuro [3,2-d] pyrimidine-based MmpL3 inhibitors as potential anti-tuberculosis agents using integrated in silico approaches

  • 期刊论文

  • 发表日期：

    2026年5月26日

查看全文
  • Anne Jibrin,
  • Adamu Uzairu,
  • Gideon Adamu Shallangwa,
  • Stephen Eyije Abechi,
  • Abdullahi Bello Umar

摘要

The continued emergence of drug resistant Mycobacterium tuberculosis highlights the pressing need for novel therapeutic strategies targeting essential and underexploited bacterial pathways. In this study, an integrated in silico approaches was employed to rationally design benzofuro [3,2-d] pyrimidine-based inhibitors targeting mycobacterial membrane protein Large 3 (MmpL3), a key transporter involved in mycolic acid biosynthesis. A structure-based e-pharmacophore model comprising six energetically significant features was developed from the MmpL3 crystal structure (PDB ID: 7C2M) and used to screen a curated ChEMBL dataset, reducing 5752 compounds to 278 candidates. Subsequent QSAR modeling demonstrated robust predictive performance (R2 = 0.65, Q2 = 0.63), enabling activity-guided prioritization. Hierarchical molecular docking and MM-GBSA calculations identified three lead compounds (D3, D12, and D16) with enhanced binding affinities (ΔGbind =  − 50.96– − 56.36 kcal/mol) relative to the reference ligand (− 49.85 kcal/mol). Molecular dynamics simulations over 200 ns confirmed the structural stability of the MmpL3–ligand complexes, with backbone RMSD values stabilizing below 2.6 Å and persistent hydrogen bonding within the binding cavity. ADMET profiling indicated favorable oral bioavailability and acceptable drug-likeness. Collectively, these findings highlight benzofuro[3,2-d]pyrimidine scaffolds as promising leads for MmpL3-targeted anti-tuberculosis drug development.